- Status:
- Red
- Decision Date:
- November 2022
Comments
RED: NICE TA922 Daridorexant for treating long-term insomnia. RED recommendation as holding position for TA compliance. ICB commissioned (Decision date - November 2023)
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
search again
